Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate‐to‐severe plaque psoriasis: the COMPASS analysis

BACKGROUND: Guselkumab is an interleukin‐23 inhibitor indicated for the treatment of moderate‐to‐severe plaque psoriasis in adults. Guselkumab has demonstrated additional benefit in patients with early inadequate response to ustekinumab. Long‐term efficacy comparisons of guselkumab and ustekinumab a...

Descripción completa

Detalles Bibliográficos
Autores principales: Diels, J., Thilakarathne, P., Cameron, C., McElligott, S., Schubert, A., Puig, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496582/
https://www.ncbi.nlm.nih.gov/pubmed/31652347
http://dx.doi.org/10.1111/bjd.18634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496582/
https://www.ncbi.nlm.nih.gov/pubmed/31652347
http://dx.doi.org/10.1111/bjd.18634

Ejemplares similares